The immunoprotein
diagnostic testing is the procedure of diagnosing the concentration
of immunoproteins in the body of a living organism. Immunoprotein is
a protein, which has immunological abilities providing immunity
against pathogenic substances or organisms. These proteins create the
integrated body system of cells, tissues, organs, or cell products to
neutralize antigens. These proteins also enable the detection of many
diseases as they exhibit an abnormal rise in the blood concentration
in the diseased state. When exposed to antigen, the levels of these
proteins raise ten to hundred folds within one or two days. The
application of these immunoproteins has changed their paradigm to
rapid testing from microbial testing.
Browse the full
Immunoprotein Diagnostic Testing Market Report at
http://www.transparencymarketresearch.com/immunoprotein-diagnostic-testing.html
The rise in the need
for quick and accurate detection of the diseases coupled with the
increasing demand for precautionary healthcare in emerging economies
is the major driving force behind the growth in the global
immunoprotein diagnostic testing industry. The powerful global
network of distributors is another factor fueling the developing
market. Apart from this, the technical advancement and the
commoditization of products are also expected to drive the market in
the coming years.
In contrast to this,
the high cost of diagnosis and the deployed base of conventional
ELISA test are the main hindrances limiting the growth of the global
immunoprotein diagnostic testing industry. However,
immunochromatography, research and development, and expansion of the
immunoprotein diagnostic testing industry in emerging economies will
cater for huge opportunities for the increment in the global
immunoprotein diagnostic testing market in near future.
Enzyme-based
immunoassay, immunoturbidity assay, immunofluorescence assay,
radioimmunoassay, chemiluminescence assay, and immunoprotein
electrophoresis are segments of immunoprotein diagnostic testing
industry based on the assay technology.
The
chemiluminescence assay market is recognized as the fastest
developing market segment of the immunoprotein diagnostic testing
industry. The sensitivity, simplicity in utilization, and the broad
array of application are the reasons behind this development.
Contrarily, the radioimmunoassay market is likely to decline as it is
being substituted by better and more secure technologies such as
chemiluminescence assay, ELISA, immunofluorescence assay, and others.
The restrictions
imposed by the governments on the utilization of radioactive
substances have significantly affected the growth in the
immunoprotein diagnostic testing market. The compliance with
regulatory firms, high cost of assay devices and safety equipment
have further hampered the growth of the radioimmunoassay market. The
immunofluorescence assay and immunoturbidity assay industries will be
developing at a moderate CAGR of around 5% during the period of 2013
to 2019.
Browse the full
Press Release Report:
http://www.transparencymarketresearch.com/pressrelease/immunoprotein-diagnostic-testing.htm
Based on the type of
immunoprotein tests, the global immunoprotein diagnostic testing
market is classified into haptoglobin diagnostic tests, complement
system protein diagnostic tests, free light chain diagnostic tests,
C-reactive protein diagnostic tests, immunoglobulin diagnostic tests,
and prealbumin diagnostic tests. Among these, the C-reactive protein
or CRP diagnostic tests market has attracted significant focus in the
past due to the efficacy of the test in diagnosing disorders related
to inflammation accurately.
Infectious disease
testing, endocrine testing, allergy testing, oncology testing,
toxicology testing, and autoimmune disease testing are the various
market segments based on the application of immunoprotein diagnostic
testing. The oncology testing market is likely to generate the
biggest share in the overall revenue the global market for
immunoprotein diagnostic testing industry is expected to generate
during the period of 2013 to 2019. The market for oncology testing
will develop at a CAGR of 6% during the period of the forecast, and
reach a value of US$4,943.0 million by the end of the forecast
period.
In 2012, the global
industry for immunoprotein diagnostic testing was valued at
US$11,019.7 million. It is expected the global immunoprotein
diagnostic testing market will reach US$15,351.0 million in the end
of the forecast period, reporting a CAGR of 5.7% during the period of
the forecast.
Abcam PLC, Siemens
AG, Enzo Life Sciences, Inc., Randox Laboratories Ltd., Thermo Fisher
Scientific, Inc., DiaSorin SPA, Fujirebio Diagnostics, Inc., Roche
Holding AG, Omega Diagnostics Group PLC, The Binding Site Group Ltd.,
and Abbott Laboratories, Inc. are the major players participating in
the immunoprotein diagnostic testing market.
Request a Brochure
of this Report:
http://www.transparencymarketresearch.com/sample/sample.php?flag=s&rep_id=1253
About Us
Transparency Market
Research (TMR) is a global market intelligence company providing
business information reports and services. The company’s exclusive
blend of quantitative forecasting and trend analysis provides
forward-looking insight for thousands of decision makers. TMR’s
experienced team of analysts, researchers, and consultants use
proprietary data sources and various tools and techniques to gather
and analyze information.
TMR’s data
repository is continuously updated and revised by a team of research
experts so that it always reflects the latest trends and information.
With extensive research and analysis capabilities, Transparency
Market Research employs rigorous primary and secondary research
techniques to develop distinctive data sets and research material for
business reports.
No comments:
Post a Comment